Brian Nowosielski

Among patients with cirrhosis receiving diuretic therapy, researchers explore the association between SGLT-2 inhibitors and the risk of serious liver outcomes.

Michael Murphy, PharmD, MBA, joined Drug Topics to present his ideas for correcting the growing issue of pharmacy deserts and unprecedented closures across the country.

Senators Warner and Thune reintroduced the ECAPS legislation improving both seniors’ access to care and pharmacists’ ability to get reimbursed for clinical services.

Researchers explored how the GLP-1 medications semaglutide and tirzepatide impact incidence rates in a variety of health-related outcomes.

With the company’s dedication to providing crucial data for pharmacy stakeholders, IQVIA’s Lead Research Director Michael Kleinrock discussed the current trends in patients’ medication use.

LEO Pharma’s topical medication was shown to be safe and effective in adult patients with moderate-to-severe hand eczema.

Amid uncertainty about the best factors for measuring and defining pharmacy deserts, researchers explored the impacts of drive time and inequities in pharmacy access.

Michael Murphy, PharmD, MBA, provided insights on his research regarding pharmacy deserts, who they impact the most, and the methods needed to improve them in the US.

With an emphasis on the factors that differentiate the future roles of pharmacists, researchers sought to better understand the career intentions of pharmacy students.

In part 4 of our interview with Michael Kleinrock, lead director of research at IQVIA, he discussed how trends in medication use are currently impacting pharmacy businesses.

Michael Murphy, PharmD, MBA, discusses how the lack of a universal definition for pharmacy deserts is leading to a significant impact on patients’ access and outcomes.

Using the Q Methodology to account for subjectivity in responses, pharmacists self-identified their professional identities.

In the researchers’ exploration of post-ICU nutritional care, they detailed the clinical pharmacist’s role and provided insights into how this role may evolve in the future.

Emphasizing the pharmacist’s essential role, researchers explored the causes, consequences, and clinical implications of polypharmacy.

IQVIA’s Lead Director of Research Michael Kleinrock discusses how federal policy has been impacting prescription drug costs in the US and where those trends are expected to go.

Amid increased advancements in diabetes management, Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discussed how these developments are currently impacting the delivery of insulin.

Researchers conducted a review of pharmacist interventions and their ability to impact the outcomes of patients with COPD.

The 2 corporations formed the Bristol Myers Squibb-Pfizer Alliance and will be offering discounted Eliquis to eligible patients starting September 8, 2025.

Researchers examined the factors attributed to self-reported resilience among diverse and community-dwelling adults during the COVID-19 pandemic.

Researchers characterized trends in COVID-19 hospitalizations by race and ethnicity among children from March 2020 to September 2023.

Michael Kleinrock, lead director of research at IQVIA Institute for Human Data Science, discusses the current trends in medication use and where these drivers may be headed in the near future.

Researchers addressed the current trends in prescription drug use and spending among Medicare Advantage beneficiaries during the first year of clinician access to a real-time prescription benefit tool.

Researchers investigated the timing of hypertension diagnosis, exploring its association with medication prescribing and long-term cardiovascular outcomes.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discusses how diabetes advancements like GLP-1s and CGM have impacted the management of insulin.

Researchers assessed the difference between hidradenitis suppurativa and other skin conditions regarding the initiating events, inflammatory signature, and molecular and clinical features of each disease.

Researchers conducted a retrospective cohort study to understand pneumococcal disease patterns, vaccine coverage, and the overall burden of the disease in adults in France.

Michael Kleinrock from IQVIA joined Drug Topics to discuss his company’s recently released report, Understanding the Use of Medicines in the US 2025.

Researchers conducted a narrative review of the insulins available for diabetes management and which pharmacological options are best in the perioperative period and within clinical care.

Researchers explored the global disease burden of allergic-related skin diseases from 1990 to 2021 and projected future disease trends.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, joins Drug Topics to discuss her extensive background in managing patients’ insulin regimens.